Meeder Asset Management Inc Atara Biotherapeutics, Inc. Transaction History

Meeder Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 08, 2021	SELL	$11.99 - $17.9 $3,704 - $5,531	-309 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$12.89 - $16.58 $3,983 - $5,123	309 New	309 $5,000
Q4 2020 Feb 09, 2021	SELL	$12.67 - $26.23 $21,247 - $43,987	-1,677 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$11.92 - $15.87 $19,989 - $26,613	1,677 New	1,677 $23,000
Q3 2019 Oct 17, 2019	SELL	$12.03 - $19.94 $5,437 - $9,012	-452 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$19.05 - $41.04 $8,610 - $18,550	452 New	452 $9,000
Q1 2019 Apr 16, 2019	SELL	$28.4 - $41.74 $104,256 - $153,227	-3,671 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$30.9 - $42.97 $113,433 - $157,742	3,671 New	3,671 $128,000
Q3 2018 Nov 02, 2018	SELL	$35.05 - $43.5 $52,014 - $64,554	-1,484 Closed	0 $0
Q2 2018 Jul 24, 2018	BUY	$35.15 - $51.45 $30,685 - $44,915	873 Added 142.88%	1,484 $0
Q1 2018 May 03, 2018	BUY	$18.0 - $48.35 $10,998 - $29,541	611 New	611 $23,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $690M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.